Keeps Biopharma Subsidiary Succeeds in Expanding Oncology Drug Distribution: “First-Half Sales Surpass Last Year’s Full-Year Figure”

[Financial News] BIXINK Therapeutics, a subsidiary of Keeps Biopharma, is accelerating its growth by expanding its oncology drug portfolio. After surpassing last year’s full-year sales in the first half of this year, the company also returned to operating profitability, putting annual sales of more than KRW 10 billion within reach.
BIXINK said on the 4th that it recorded cumulative first-half sales of KRW 5.6 billion this year. That was a 235% increase from the same period last year and exceeded its full-year sales of KRW 5.1 billion last year in just six months.
Sales growth is accelerating particularly rapidly. BIXINK’s sales rose from KRW 3.5 billion in 2024 to KRW 5.1 billion last year, and the company is targeting more than KRW 10 billion this year. If it reaches that goal, its business scale will have nearly tripled in two years. Operating profit also turned positive in the first half.
The main driver of this growth is the expansion of its oncology drug portfolio. First-half sales of Nerlynx, its flagship breast cancer treatment, increased 58% from the same period last year. Five oncology drugs covered by an exclusive distribution agreement with Teva-Handok are also quickly contributing to sales. These products accounted for 18% of total first-half sales.
Overseas sales are also emerging as a new growth engine. Mucosamin, a treatment for oral mucositis in cancer patients for which BIXINK holds the Asian rights, expanded its sales territories to Taiwan, Thailand, and Malaysia, driving sales to more than eight times the previous year’s level.
The company plans to sustain its growth by adding new products, leveraging its oncology-focused sales and marketing organization and its network of tertiary hospitals and cancer specialists. Its focus is on expanding its specialized oncology portfolio by adding newly introduced products to its existing Nerlynx and Longquix offerings.
An industry source said, "In the prescription drug business, it is important not only to grow individual products but also to improve sales efficiency by adding products to an existing sales network." The source added, "In BIXINK’s case, the number of products that can use its existing oncology sales network is increasing, so the portfolio expansion can be seen as entering a stage where it is translating into growth in overall business scale."
Kim Man-gi, an executive at BIXINK, said, "As our accumulated expertise and sales capabilities in oncology are translating into results, we expect record-high sales of more than KRW 10 billion this year." He added, "We will continue to strengthen the competitiveness of our oncology drug portfolio by introducing new products."
[email protected] Kim Kyung-ah Reporter